Effect of calcium and vitamin D supplementation with and without collagen peptides on bone turnover in postmenopausal women with osteopenia.
Study Goal
The researchers aimed to examine the efficacy and tolerability of calcium, vitamin D, and collagen peptides (CPs) supplementation in reducing bone turnover markers (P1NP and CTX) in postmenopausal women with osteopenia.
Results Summary
Group A (calcium, vitamin D, and CPs) showed significant reductions in P1NP (13.1%) and CTX (11.4%), while Group B (calcium and vitamin D alone) showed no changes. Group A also had better compliance and no adverse events compared to Group B.
Population
Postmenopausal women with osteopenia (n=51).
Effective Dosage
Group A: 500 mg elemental calcium (as calcium lactate), 400 IU vitamin D3, and 5 g CPs daily; Group B: 500 mg elemental calcium (as calcium carbonate) and 400 IU vitamin D3 daily.
Duration
3 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
3-month supplementation of calcium, vitamin D with bioactive collagen peptides (CPs) | decrease | P1NP levels | postmenopausal women with osteopenia | 13.1% | significantly decreased | #1 |
3-month supplementation of calcium, vitamin D with bioactive collagen peptides (CPs) | decrease | CTX levels | postmenopausal women with osteopenia | 11.4% | decreased | #2 |
3-month supplementation of calcium, vitamin D without bioactive collagen peptides (CPs) | no change | P1NP levels | postmenopausal women with osteopenia | no significant change | did not change | #3 |
3-month supplementation of calcium, vitamin D without bioactive collagen peptides (CPs) | no change | CTX levels | postmenopausal women with osteopenia | no significant change | did not change | #4 |
3-month supplementation of calcium, vitamin D with bioactive collagen peptides (CPs) | increase | compliance | postmenopausal women with osteopenia | - | presented better compliance | #5 |
3-month supplementation of calcium, vitamin D with bioactive collagen peptides (CPs) | decrease | adverse events | postmenopausal women with osteopenia | - | no adverse events | #6 |
3-month supplementation of calcium, vitamin D without bioactive collagen peptides (CPs) | increase | adverse events | postmenopausal women with osteopenia | - | adverse events | #7 |
calcium, vitamin D and collagen peptides (CPs) supplements | decrease | bone turnover | postmenopausal women | - | reduction of the increased bone turnover | #8 |
addition of collagen peptides (CPs) in a calcium and vitamin D supplement | increase | bone metabolism | - | - | may enhance its already known positive effect | #9 |
OBJECTIVES: Collagen peptides (CPs) seem to exert beneficial effects on bone and may have a role as a treatment option. In the present randomized prospective study, we aimed to examine the efficacy, as expressed by changes in P1NP and CTX, and the tolerability of 3-month supplementation of calcium, vitamin D with or without bioactive CPs in postmenopausal women with osteopenia. METHODS: Fifty-one female, postmenopausal women with osteopenia were allocated to two groups: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 and group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily. RESULTS: In group A, the P1NP levels significantly decreased by 13.1% (p<0.001) and CTX levels decreased by 11.4% (p=0.058) within 3 months of supplementation. In group B, P1NP and CTX did not change. Group A presented better compliance in comparison to group B and no adverse events contrary to group B. CONCLUSIONS: These findings may reflect the reduction of the increased bone turnover in postmenopausal women with the use of calcium, vitamin D and CPs supplements. The addition of CPs in a calcium and vitamin D supplement may enhance its already known positive effect on bone metabolism. Clinical Trial ID: NCT03999775.